ABSTRACT PURPOSE. To assess the ability of circulating tumor DNA (ctDNA)-based testing to identify patients with HER2 (encoded…
Guardant Health Expands Guardant360 ® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling…
New Guardant360 Response™ blood test predicts treatment response to immunotherapy and targeted therapy, up to eight weeks…
New Guardant360 Response™ blood test predicts treatment response to immunotherapy and targeted therapy, up to eight weeks…
Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-st…
--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management…
- Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late…
- Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late…
Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-st…
New Guardant360 Response™ blood test predicts treatment response to immunotherapy and targeted therapy, up to eight weeks…
New Guardant360 Response™ blood test predicts treatment response to immunotherapy and targeted therapy, up to eight weeks…
Guardant Health Expands Guardant360 ® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling…
New Guardant360 Response™ blood test predicts treatment response to immunotherapy and targeted therapy, up to eight weeks…
Phase 2 trial of Amgen’s investigational KRAS G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients…
The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes…
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of…
Phase 2 trial of Amgen’s investigational KRAS G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients…
Phase 2 trial of Amgen’s investigational KRAS G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients…
Phase 2 trial of Amgen’s investigational KRASG12C inhibitor, sotorasib, demonstrated comparable efficacy between patients…
REDWOOD CITY, Calif.--(Business Wire)--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and…
Phase 2 trial of Amgen’s investigational KRAS G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients…
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at…
- Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data…
- Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data…
- Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data…
- Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data…
- Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data…
Phase 2 trial of Amgen’s investigational KRAS G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients…
Phase 2 trial of Amgen’s investigational KRAS G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients…
Phase 2 trial of Amgen’s investigational KRASG12C inhibitor, sotorasib, demonstrated comparable efficacy between patients…
Phase 2 trial of Amgen's investigational KRAS G12C inhibitor, sotorasib, demonstrated comparable efficacy between patients…
Fo For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is…
REDWOOD CITY, Calif.--( BUSINESS WIRE )-- For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an…
Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Smal…
Consistent with studies, across various treatments and indications,1-9 showing Guardant Health blood test provides early…
March 26, 2021 12:05 UTC Consistent with studies, across various treatments and indications, 1-9 showing Guardant Health blood…
Consistent with studies, across various treatments and indications, 1-9 showing Guardant Health blood test provides early…
REDWOOD CITY, Calif.--(Business Wire)--For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an…
Consistent with studies, across various treatments and indications, 1-9 showing Guardant Health blood test provides early…
- For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is…
- For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is…
- For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is…
- For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is…
- For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is…
- For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is…
For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is often…
Consistent with studies, across various treatments and indications, 1-9 showing Guardant Health blood test provides early…
Consistent with studies, across various treatments and indications, 1-9 showing Guardant Health blood test provides early…
Consistent with studies, across various treatments and indications, 1-9 showing Guardant Health blood test provides early…